SuperworthTrevi Therapeutics shares outstanding TRVI
Diluted shares outstanding, averaged over each quarter, from 2018.
- Latest quarter, to Jun 30, 2026
- 156.6M
- On a year earlier
- +20.1%
- more shares
Trevi Therapeutics had 156.6M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 20.1% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 145.5M | +37% |
| FY2024 | 106M | +7% |
| FY2023 | 99.5M | +1% |
| FY2022 | 98.1M | +226% |
| FY2021 | 30.1M | +63% |
| FY2020 | 18.4M | +3% |
| FY2019 | 17.8M | +3966% |
| FY2018 | 438.6K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 156.6M | +20% | |
| Q1 FY26 | 145.6M | +24% | |
| Q4 FY25 | 145.5M | +37% | |
| Q3 FY25 | 145.1M | +43% | |
| Q2 FY25 | 130.4M | +29% | |
| Q1 FY25 | 117.6M | +18% | |
| Q4 FY24 | 106M | +7% | |
| Q3 FY24 | 101.3M | +2% | |
| Q2 FY24 | 101M | +2% | |
| Q1 FY24 | 99.5M | +1% | |
| Q4 FY23 | 99.5M | +1% | |
| Q3 FY23 | 99.3M | +44% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Trevi Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.